CLDX Celldex Therapeutics Inc

$25.07

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.

Website: https://www.celldex.com

Sector
LIFE SCIENCES
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
744218
Address
53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, US
Valuation
Market Cap
$1.21B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
1.63
Performance
EPS
$-2.45
Dividend Yield
—
Profit Margin
0.00%
ROE
-26.80%
Technicals
50D MA
$19.87
200D MA
$28.49
52W High
$47.00
52W Low
$14.40
Fundamentals
Shares Outstanding
66M
Target Price
$62.08
Beta
1.59

CLDX EPS Estimates vs Actual

● Estimated
● Actual

CLDX News & Sentiment

Nov 10, 2025 • Benzinga SOMEWHAT-BULLISH
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government shutdown may soon conclude.
Oct 30, 2025 • Benzinga NEUTRAL
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition - Celldex Therapeutics ( NASDAQ:CLDX )
--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium--
Oct 10, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Are Medical Stocks Lagging ANI Pharmaceuticals ( ANIP ) This Year?
Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.
Sep 09, 2025 • Benzinga NEUTRAL
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - Celldex Therapeutics ( NASDAQ:CLDX )
HAMPTON, N.J., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc.
Sep 09, 2025 • GlobeNewswire NEUTRAL
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
HAMPTON, N.J., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the ...
Aug 20, 2025 • Benzinga NEUTRAL
Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics ( NASDAQ:CLDX )
Barzolvolimab cut mast cells by -36 vs. -2.7 in placebo at 12 weeks. Despite cell depletion, no symptom or endoscopic improvement in eosinophilic esophagitis. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Sentiment Snapshot

Average Sentiment Score:

-0.003
50 articles with scored sentiment

Overall Sentiment:

Neutral

CLDX Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.85
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: 1.2%
May 08, 2025
Mar 31, 2025 (Pre market)
-0.12 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.69
  • Whisper: —
  • Surprise %: -17.4%
Feb 27, 2025
Dec 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.71
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: 0.6%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $-0.64
  • Estimate: $-0.67
  • Whisper: —
  • Surprise %: 4.5%
Aug 08, 2024
Jun 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $-0.54
  • Estimate: $-0.59
  • Whisper: —
  • Surprise %: 8.5%
May 06, 2024
Mar 31, 2024 (Post market)
0.13 Surprise
  • Reported EPS: $-0.56
  • Estimate: $-0.69
  • Whisper: —
  • Surprise %: 18.8%
Feb 26, 2024
Dec 31, 2023 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.83
  • Estimate: $-0.74
  • Whisper: —
  • Surprise %: -12.2%
Nov 02, 2023
Sep 30, 2023 (Post market)
-0.13 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.68
  • Whisper: —
  • Surprise %: -19.1%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $-0.65
  • Estimate: $-0.67
  • Whisper: —
  • Surprise %: 3.0%

Financials